Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study by Borromeo, Gelsomina L et al.
STUDY PROTOCOL Open Access
Is bisphosphonate therapy for benign bone
disease associated with impaired dental healing?
A case-controlled study
Gelsomina L Borromeo
1*, Caroline Brand
2,3, John G Clement
1, Michael McCullough
1, Wendy Thomson
1,
Elly Flitzanis
1 and John D Wark
2
Abstract
Background: Bisphosphonates are common first line medications used for the management of benign bone
disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the
jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical
co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a
devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less
dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis.
It is hypothesised that long-term (more than 1 year’s duration) bisphosphonate use for the treatment of post-
menopausal osteoporosis or other benign bone disease is associated with impaired dental healing.
Methods/Design: A case-control study has been chosen to test the hypothesis as the outcome event rate is likely
to be very low. A total of 54 cases will be recruited into the study following review of all dental files from oral and
maxillofacial surgeons and special needs dentists in Victoria where potential cases of delayed dental healing will be
identified. Potential cases will be presented to an independent case adjudication panel to determine if they are
definitive delayed dental healing cases. Two hundred and fifteen controls (1:4 cases:controls), matched for age and
visit window period, will be selected from those who have attended local community based referring dental
practices. The primary outcome will be the incidence of delayed dental healing that occurs either spontaneously or
following dental treatment such as extractions, implant placement, or denture use.
Discussion: This study is the largest case-controlled study assessing the link between bisphosphonate use and
delayed dental healing in Australia. It will provide invaluable data on the potential link between bisphosphonate
use and osteonecrosis of the jaws.
Background
Bisphosphonates are non-metabolised analogues of pyr-
ophosphates that are often prescribed to treat osteo-
porosis, Paget’s disease of bone, metastatic osteolytic
lesions associated with breast cancer, multiple myeloma,
severe forms of osteogenesis imperfecta and moderate
to severe hypercalcemia associated with malignancies
[1-4]. In recent times intravenous bisphosphonates have
also been advocated for the management of osteoporosis
[5-7].
Post-menopausal osteoporosis is a common condition
[8]. Less potent bisphosphonates such as alendronate
and risedronate are first-line therapy for the treatment
of post-menopausal osteoporosis, especially following
a minimal-trauma fracture [9-11]. Paget’s disease is
another relatively common benign bone disorder for
which bisphosphonates are first-line treatment [12]. By
2006, over 19 million prescriptions for bisphosphonates
were dispensed worldwide suggestive of a good safety
profile and benefit in osteoporosis management [13].
Adverse events related to bisphosphonate usage have
centred largely around gastrointestinal and renal safety,
bone, joint or muscle pain and the development of
acute phase reactions [14]. Several recent reports have
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sphonate use, especially intravenous (IV) zoledronate or
pamidronate, and jaw osteonecrosis [15-21]. Other stu-
dies have not found any association between bishospho-
nate use and ONJ [6]. A study assessing once yearly
zoledronate for osteoporosis management in 8000 indi-
viduals reported, following separate case adjudication, a
single episode of ONJ in each of the placebo and zole-
dronic acid groups [6]. The length of this study was
only three years whereas most ONJ has been reported
in patients taking bisphosphonates for longer periods of
time. In a recent survey of over 8000 respondents, ONJ
had a prevalence of 0.10% (95% confidence interval
0.05% to 2.0%) [22]. Previously, similar but less frequent
presentations with jaw osteonecrosis occurred following
radiotherapy (Ruggerio et al., 2004) or occupational
exposure to phosphorus [23]. In many of the reports,
jaw osteonecrosis occurred in the setting of malignancy,
in particular, multiple myeloma [24-26] or breast cancer
[18,19,26]. Recent work has suggested that in myeloma
patients, zoledronate and pamidronate are associated
with a 10% and 3% incidence of jaw osteonecrosis at
36 months, respectively [25]. In contrast, the prevalence
of jaw osteonecrosis with bisphosphonate treatment in a
large retrospective case series was 2.4% among myeloma
patients and 1.2% among breast cancer patients [26].
There is some published evidence that chronic low-
dose bisphosphonate treatment for osteoporosis or other
benign bone disease is associated with jaw osteonecrosis
[18,27]. However, randomised controlled trials of
bisphosphonates in osteoporosis have not demonstrated
an increased risk of jaw osteonecrosis. The development
of ONJ has been linked to duration of exposure to
bisphosphonates, and hence a higher cumulative dose,
longer duration of treatment, hence prolonged survival,
as well as potential co-morbidities such as prednisolone
or thalidomide use [26]. Poor periodontal status
together with dental interventions, in particular extrac-
tions, implants or trauma from dentures for example,
significantly increase the risk of developing ONJ in this
patient cohort [17,19,20,26,28].
The exact mechanism by which bisphosphonates may
contribute to impaired resistance to injury or impaired
healing of the maxilla or mandible and to osteolytic
destruction, remains unclear. However, suppression of
bone turnover via actions on osteoclasts seems to play a
substantial role [29,30]. Bisphosphonates are not the
only medications with this action. Other drugs such as
denosumab (a RANKL antibody which is indicated in
cancer patients) and bevacizumab (a human monoclonal
antibody to vascular endothelial growth factor) have the
potential to alter osteoclast differentiation and function
and as such has also been implicated in ONJ [31,32].
Although ONJ associated with bisphosphonate use
appears to resemble osteoradionecrosis seen following
jaw radiotherapy, they are now considered different dis-
ease entities [33]. Conventional therapy of this latter
complication involves local debridement, irrigation and
antibiotics [34]. However, this strategy has yielded
mixed results in bisphosphonate-associated osteonecro-
sis, and may contribute to further tissue breakdown,
resulting in large fistulas [35].
While jaw osteonecrosis is a devastating end-stage out-
come that is currently difficult to manage, various forms
of delayed dental healing may be a less clinically dramatic
and, therefore, poorly-recognised complications of
bisphosphonate use. Currently, the likelihood of dental
complications during bisphosphonate therapy for treat-
ment of post-menopausal osteoporosis or other benign
bone disease is uncertain. It is unclear what factors pre-
dispose patients to these events [36,37]. Given the large
numbers of patients receiving long-term bisphosphonate
therapy, particularly in benign bone disease, that a high
level of professional and public concern has arisen about
the issue, and the fact that we are living in an ageing
population making the likelihood of levels of osteoporosis
increasing, understanding the prevalence and risk of
bisphosphonates and jaw osteonecrosis is paramount.
Hypothesis
The hypothesis to be tested is that long-term (more
than 1 year’s duration) bisphosphonate use for the treat-
ment of post-menopausal osteoporosis or other benign
bone disease is associated with impaired dental healing.
Methods
Study design
A case-control study has been chosen to test the
hypothesis as the outcome event rate is likely to be very
low (Figure 1).
Definitions
Delayed dental healing
Delayed dental healing (a precursor to osteonecrosis of
the jaw) is defined as a persistent breach in the oral
mucosa and/or exposure of bone in the mandible or
maxilla that:
￿ fails to heal within 6 weeks as documented by a den-
tist despite usual therapy;
￿ occurs either following a dental procedure, for
example a tooth extraction or crown insertion, or spon-
taneously, with or without osteonecrosis.
Osteonecrosis of the jaw
￿ Exposed bone in the maxillofacial area that occurred
in association with dental surgery or spontaneously with
no evidence of healing
Borromeo et al. BMC Musculoskeletal Disorders 2011, 12:71
http://www.biomedcentral.com/1471-2474/12/71
Page 2 of 10￿ No evidence of healing after 6 weeks of appropriate
evaluation and dental care
￿ No evidence of the following bone pathology that
might explain the findings: metastatic disease in the jaw
or osteoradionecrosis.
Setting and study time frames
The study will take place in Victoria, the second most
populous State in Australia with a population of
approximately 5 million people. The visit window period
s t u d yp e r i o dw i l lb eM a r c h1
st 2006 until August 31
st
2006. Participants in the study will have been treated in
specialist oral and maxillofacial and special needs dentis-
try settings during the visit window period. Control sub-
jects will have attended local community based referring
dental practices. A flow diagram of the study protocol is
depicted in Figure 2.
Dental Specialist Recruitment
Specialist dental recruitment will involve contacting
a l lr e g i s t e r e do r a la n dm a x i l l o f a c i a ls u r g e o n sa n d
special needs dentists who were actively practicing dur-
ing March 2006 through to the end of August 2006.
All registered specialists listed in the Yellow Pages
telephone directory will be cross-matched with those
currently registered with the Australian Health Prac-
titioner Regulation Agency. The researchers will
also present the study to a Victorian Branch meeting of
the Australian and New Zealand Association of Oral
and Maxillofacial Surgeons. All public hospital dental
specialty clinics in Victoria and associated specialist
dental practitioners will be identified. All registered
specialist dental practitioners will be invited to partici-
pate in the case-controlled study via introductory
mail out.
 Outcome 
  CASES 
 
(disease = impaired 
dental healing) 
 
CONTROLS 
 
(no disease = normal 
dental healing) 
Exposure of interest  Exposed to oral 
bisphosphonate 
therapy 
 
 
            ?? 
 
 
           ?? 
not exposed to oral 
bisphosphonate 
therapy 
 
 
            ?? 
 
 
           ?? 
XX YY
Figure 1 Case-controlled study design.
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mail at 2-weeks and telephone at 4-weeks. Once specialists
agree to participate, then the respective practice will be
contacted to determine a suitable time to view patient files
and identify potential cases. All files within the 6-month
visit window period will be screened and only those meet-
ing the age and visit window criteria will be reviewed for
further potential case information. Once potential cases
are determined then they will be presented to the Case
Adjudication Panel (CAP) (see further details below).
 
 
All OMFS in 
Victoria 
All SND Specialists in 
Victoria 
Decline 
participation 
Agree to 
participation 
Agree to 
participation 
Decline 
participation 
Screening of files meeting age and 
visit window criteria 
Identified potential cases to 
present to CAP 
Yes a potential 
case 
No not a 
case 
no further 
data 
collection 
Decline to participate  
(non-participating case) 
Agree to participate 
(participating case) 
telephone interview and 
medical information 
review 
no telephone 
interview 
invitation to 
participate 
Match for controls 
from practice where 
case was referred 
(1:4 case:controls) 
Match for controls 
from practice where 
case was referred 
(1:4 case:controls) 
Figure 2 Flow diagram of study protocol.
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Recruitment of individuals for the study is a two-step
process, ascertainment of potential cases through dental
record review then verification by a case adjudication
panel (CAP). The research team would visit each partici-
pating practice to identify potential cases from the den-
tal records, which could then in turn be presented to
the case adjudication panel. Each specialist practitioner
would be required to give consent to have patients in
their practice contacted by the research team.
Participant ascertainment will occur through consecu-
tive screening of oral and maxillofacial and special
needs dental specialist records in private practices and
public hospitals by trained research staff. Once a case
has been confirmed by CAP, each specialist practitioner
would be required to give consent to have patients in
their practice contacted by the research team.
To be eligible for participation, the dental record
should indicate that the potential participant is:
￿ age ≥ 50 years
￿ has a dental wound that failed to heal within 6 weeks
￿ had a qualifying visit during the window period.
The exclusion criteria are:
￿ A history of active malignancy or malignancy within
five years (excluding basal or squamous cell carcinoma).
￿ Previous radiotherapy field that included the jaws.
￿ Bisphosphonate use for any indication other than
post-menopausal osteoporosis or other benign bone
disease.
In order for potential cases to be identified from the
patient files, the research team reviewing the clinical
notes need to be able to identify delayed dental healing.
It is expected that the term “delayed dental healing” as a
potential descriptor is unlikely to appear in the clinical
notes, as there would be variability in clinical descrip-
tions amongst specialists. As such a number of file ter-
minology descriptors will be used to help identify
potential cases of DDH and these are outlined within
‘data collection methods’ below.
All records identified as potential cases of delayed
dental healing will be presented to the CAP for verifica-
tion for inclusion or exclusion. The CAP will include a
Chair who will be an independent specialist endocrinol-
ogist, 2 other medical practitioners and three dentists
(one Oral Medicine Specialist, one oral and maxillofacial
surgeon and one forensic dentist/bone biologist).
A quorum of 4 (2 dental and 2 medical) will be required
at each CAP meeting.
At each CAP meeting all de-identified potential cases
will be presented without the panel’sk n o w l e d g eo f
bisphosphonate history and medical status. The records
presented will be assessed according to the previously
stated inclusion and exclusion criteria.
Once verified as a definite case by the CAP, the indivi-
dual will be contacted via mail to seek informed written
consent for participation in the study. Non-responders
will consist of two main groups; individuals who do not
wish to participate and those who cannot be contacted
(e.g. changed address or deceased).
Recruitment of Control Subjects
Each case will be matched with four controls randomly
selected from those who have undergone dental treat-
ment at the same dental practice from which the case
originated. If access cannot be obtained to records
from the originating dental practice, then a similar
type of practice e.g. private practice or hospital - based
practice, within a 10 km radius will be approached to
provide control subjects. They will be matched for age
(>50 years), gender and visit window period and will
have no known defect in dental wound healing. If con-
trols cannot be matched to the 6-month visit window
period then they will be matched to within 12 months
of the visit window period. Controls will be contacted
by mail as for cases to obtain informed consent to
study participation.
Data Collection Methods
Data collection will involve collecting information per-
taining to demographics, delayed dental healing, bispho-
sphonate history and medical history. Data collection
forms and telephone interviews for controls will be the
same as that used for cases.
Part 1: Demographic information
Specialist information, patient details (name, date of
birth, gender, address and telephone number), name of
referring practitioner, referring practitioner contact
details, date of presentation of oral problem and referral
to specialist date will be collected initially. A list of all
dates within the visit window period together with an
outline of each visit will be recorded. The demographic
data will be coded for each individual and the code used
in all subsequent data collection in order to de-identify
information as per ethical requirements.
Part two: Delayed dental healing information
Each patient file identified within the visit window per-
iod will be analysed and information relating to the pre-
sence of an oral diagnosis (diagnosis, site, precipitant,
treatment, outcome, biopsy report, radiographic investi-
gation), bisphosphonate history and medical history (co-
morbidities and medications) will be recorded.
The diagnosis will consist of the presence of either
oral ulceration (“break in mucosa but no bone visible”)
or bone necrosis defined as “bone on view”.An u m b e r
of key words will be used when reviewing patient
histories as a number of descriptors can be used to
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healing socket, pus, exudate, swelling, draining sinus,
dry socket, bone sloughing, sore sockets, OAC, oroantral
communication, healing not completed, fistula, OAF,
oroantral fistula, exposed bone and infection.
Information regarding site of the lesion will be further
subdivided into single versus multiple sites, quadrant
involved, palatal, lingual, buccal or labial orientation and
tooth area (one to eight). The main precipitants listed
can include tooth extraction, implant insertion, removal
of pathological lesion, denture use, spontaneous, no
obvious precipitant or other. In each case the date of
the precipitant will be recorded. If the precipitant is not
recorded in the history this will be marked as such on
the data collection form.
Outcome of the delayed dental healing will be
recorded by including treatment modalities such as anti-
biotics, mouthwashes/irrigation, debridement or other,
date of the last review together with wound status
(healed completely, healed partially, no healing or not
recorded) and progress of the wound at the last visit
(worse, stable, improving or not recorded). Details
regarding any biopsy or radiographic analysis will also
recorded.
Part 3: Medical History
Detailed information relating to potential cancer history
including type, date of diagnosis, remission status, radio-
therapy to the jaw and chemotherapy will be recorded
as this is a key exclusion criterion. Other co-morbidities
will be recorded including lung disease, heart disease,
kidney disease, organ transplant, diabetes, rheumatoid
arthritis or other connective tissue conditions together
with smoking, tobacco and alcohol intake as these may
contribute to delayed dental healing.
Part 4: Medication history
A detailed description of oral glucocorticoids (start/stop
dates, current dose and cumulative dose), hormone
replacement therapy and other medications including
raloxifene, calcitriol, tibolone, teriparatide and strontium
will be recorded.
If a bisphosphonate has been prescribed, the type will
be recorded including alendronate, risedronate, tiludro-
nate, pamidronate, zoledronate or etidronate together
with indication for use (osteoporosis, Paget’sd i s e a s e ,
glucorticoid-induced osteoporosis, metastatic disease,
hypercalcemia). Doses of all bisphosphonates including
start and stop dates and current doses will be recorded
to allow calculation of cumulative drug doses.
Telephone interview
A telephone interview will be conducted with all con-
senting participants in order to confirm inclusion/exclu-
sion criteria (most of which may already be evident
from the patient’s dental file) and to determine socio-
economic status, dental health information and a
medical history check including bisphosphonate history,
medication profile and smoking history. The telephone
interview will last approximately 10 minutes. The tele-
phone questionnaire will be modelled on the Adult Oral
Health Survey [38] and include questions relating
to dental health and general information such as socio-
economic status and educational status. A medication
check list will also be completed with each case regard-
l e s so ft h ed a t ac o l l e c t e di nt h eo r i g i n a ld a t ac o l l e c t i o n
form in order to cross match bisphosphonate history,
other medical history which could contribute to
impaired wound healing and smoking history.
Ethics Approval
Human Research and Ethics Committee approvals have
been obtained from: Melbourne Health (2005.242) (hos-
pital and private practice cases and controls), Austin
Heath (H2006/02599; H2010/03794), The Alfred (17/
09), Barwon Heath (10/99), Dental Health Services Vic-
toria (197), Southern Health (09069A), St Vincent’s
Hospital (009/09) and Western Health (2005.242).
Statistical Analysis
Demographic and clinical characteristics of cases and
controls will be presented to assess whether these vari-
ables are associated with delayed dental healing.
Power and sample size
The sample size estimate is based upon the assumption
that the overall prevalence of bisphosphonate use in
post-menopausal women is around 10%. Based on Aus-
tralian Pharmaceutical Benefits Scheme (PBS) and Aus-
tralian Bureau of Statistics (ABS) data the upper limit
estimate is 19% [39]. Assuming that approximately 50%
of these patients have used bisphosphonate for at least
one year, then 10% prevalence of long-term use in this
population appears to be a reasonable estimate. It is
hypothesised that the prevalence of bisphosphonate use
among those with delayed dental healing may be greater
than 10%. A recent case series of patients with frank jaw
necrosis found that all were treated with bisphospho-
nates [19]. We infer from this that the true proportion
of women with DDH taking bisphosphonates may be
greater than 30% - 50%. Given the expected low preva-
lence of DDH, the study plans to recruit ‘controls’ and
‘cases’ in a ratio of 4:1. An observed prevalence of
greater than or equal to 30% bisphosphonate use
amongst women with DDH would correspond to an
odds ratio of around 3.85. Hence, for the purpose of
this study, the minimum detectable difference will corre-
spond to an OR greater than or equal to 3.85. This
value is based upon a conservative estimate of the effect
expected, rather than what is considered clinically
important. The most relevant measure of clinical impor-
tance will be one derived from a cohort study, that
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sented in terms of a relative and/or absolute risk of
delayed dental healing. Whilst ideal, this would require
a very large sample and long-term follow-up.
A total sample of around 269 subjects (54 cases and
215 controls) will provide 90% power to detect a true
OR of at least 3.85, given the expected prevalence of
10% bisphosphonate use amongst post-menopausal
women in the community.
The relationship between bisphosphonate use and
delayed dental healing will be assessed using a multivari-
ate logistic model incorporating age, duration of expo-
sure, relevant co morbidities, concurrent treatment, and
other potential confounders as covariates.
T h ep r e v a l e n c eo fD D Hi nt h et a r g e tp o p u l a t i o nw i l l
be estimated using data collected to determine case
numbers in both bisphosphonate-treated and non-
bisphosphonate-treated patients. We will also record
cases of DDH occurring in non-bisphosphonate-treated
patients with a diagnosis of benign bone disease where
bisphosphonates may be indicated (i.e. osteoporosis,
Paget’s disease of the bone).
Outcome measures
Primary outcome measures
The primary outcome will be the incidence of delayed
dental healing that occurs either spontaneously or fol-
lowing dental treatment such as extractions, implant
placement, or denture use.
Potential covariates
Potential covariates include those data collected, which
increase our knowledge of the potential to develop
DDH. These include co-morbidities (medication his-
tory, smoking history, other medical conditions), oral
hygiene habits and demographics (socioeconomic
status, nationality).
Bisphosphonate use is considered an explanatory vari-
able, which is also our exposure of interest.
Discussion
The present study seeks to determine the level of
delayed dental healing that occurs either spontaneously
or after dental procedures such as tooth extraction and
how this relates to bisphosphonate usage. Delayed den-
tal healing may be an earlier or less advanced lesion
compared to ONJ but with a similar pathogenesis. By
observing delayed dental healing as well as ONJ we may
therefore more broadly describe bisphosphonate asso-
ciated dental disorders and increase our power to find
an association between bisphosphonate use and asso-
ciated dental disorders. It is imperative to obtain a bet-
ter understanding of this condition and its potential
links to bisphosphonate use as it is often refractory to
treatment and can lead to significant morbidity
including bone sequestration, intraoral and extraoral fis-
tula formation, secondary paraesthesia and pathological
jaw fractures. The link between this and bisphosphonate
use is paramount as there are a number of studies
reporting the incidence of jaw osteonecrosis (a potential
sequelae for delayed dental healing) to be as high as
0.09 - 0.34% in patients receiving oral and 6.7-9.1% in
patients receiving intravenous bisphosphonates following
dental procedures [40]. Furthermore, whilst the inci-
dence of ONJ in osteoporosis patients in relation to
bisphosphonate use has been reported to occur after
prolonged treatment (greater than 3 years), it has been
reported following 6-month use [41]. On the other
hand, other data suggest an extremely low prevalence/
incidence of ONJ in patients treated with bisphospho-
nates for osteoporosis and other metabolic bone dis-
orders. Although an association between ONJ and
bisphosphonate use has been suggested by case series,
professional surveys and register data, there is a lack of
controlled, population-based data. A key aim of the pre-
sent study is to obtain such controlled data. By record-
ing the prevalence of delayed dental healing and ONJ
that occur in the absence of bisphosphonate use we
hope to be able to estimate the true risk of these disor-
ders in association with bisphosphonate exposure.
A case-controlled study design has been selected over
a prospective cohort study. Whilst both are observa-
tional studies that could further knowledge of delayed
dental healing, ONJ and bisphosphonate use, the former
study design has a number of advantages. First, it will
allow us to study an outcome with a potentially low
incidence, less than 1% in patients with osteoporosis or
Paget’s disease [42]. Second, this approach will minimize
the problem posed by a long latency between exposure
to bisphosphonate therapy and the outcome of delayed
healing and subsequent ONJ, something which cannot
be accounted for easily in a prospective cohort study,
except by extended follow-up. Third, we will be able to
study the effects of other potential risk factors for
delayed healing such as medical history including
bisphosphonate usage, smoking history, dental hygiene,
dental trauma including tooth extractions and implant
placement, and denture usage on the outcome of inter-
est, namely delayed dental healing. It is understood that
a prospective cohort study would provide the most reli-
able assessment of the incidence of delayed healing,
ONJ and bisphosphonates but to date such studies have
not been conclusive [14].
One of the major limitations of this case-controlled
study design is that it is reliant on information as it is
recorded in the medical or dental history that may be
incomplete and is subject to clinician bias and
researcher interpretation. This is compounded by the
fact that in 2006 there was considerable controversy
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and the definition of the condition. Furthermore,
resources required to access and collect data from thou-
sands of medical and dental histories could result in a
prolonged study period.
The present study also relies on recruitment of specia-
lists to allow access to patient records followed by
recruitment of cases and controls. All oral and maxillo-
facial specialists and special needs dentists in the state
of Victoria will be invited to participate in the study but
it will be difficult to control for ascertainment bias. Are
practitioners who see delayed dental healing and ONJ
more willing to allow review of their patient records?
A r et h o s ew h oh a v eag r e a t e ri n t e r e s ti nt h er o l ep l a y e d
by bisphosphonates more likely to want to become
involved? It is difficult to control for this even with the
use of random sampling because practitioners’ consent
is required to allow file review. To some degree the
same can also be said for patients with delayed dental
healing. The patient information and consent brochure
stipulates that this is an important study to further our
understanding of the link between delayed dental heal-
ing and bisphosphonate use. Whether an individual who
has taken a bisphosphonate may be more or less likely
to participate is difficult to determine. Another potential
limitation of the study is recollection bias given that
some data will be collected via participant telephone
interview. Furthermore, control subjects reading the
patient information and consent brochure may feel that
the study does not really benefit them and hence may
be less likely to respond. The same can also be said for
the general dental practitioners via whom the control
subjects will be identified. Ift h e yh a v el i t t l ee x p e r i e n c e
with patients taking bisphosphonates or delayed dental
healing, then they may have little motivation to allow a
third party to access their patient records.
A key feature of the present study relates to the defi-
nition of DDH and ONJ. In 2005 the definition of osteo-
necrosis of the jaw was unclear and constantly changing
in the literature and as such it was difficult to adhere to
a single definition. The main disparity at the time was
related to the length of time a wound took to heal
before it fell into the category of osteonecrosis of the
jaw. Initial healing, that is re-epithelialisation, of dental
wounds such as those from dental extractions usually
takes between 1 and 2 weeks [43]. Once the clot forms,
fibrin and connective tissue begins to develop before the
wound (in this case a dental socket) is closed over by
epithelium. It then takes some weeks for the underlying
socket to fill with bone and healing to be complete.
Hence up to 6 weeks for healing of a dental wound
would be reasonable taking into account potential
effects of delayed healing from medical co-morbidities
such as steroid use or development and subsequent
healing from complications such as a dry socket.
Furthermore, in 2008, a report from the task force of
the American Society for Bone and Mineral Research
proposed that a “suspected” case of ONJ would be
defined as “an area of exposed bone in the maxillofacial
region that had been identified by a health care provider
and have been present for less that 8 weeks” which was
supported by others [42,44]. By this time, soft tissue clo-
sure and exposed bone would no longer be present.
ONJ would then be the definitive diagnosis if greater
than 8 weeks had lapsed for healing to occur [42,45,46].
The current definition for bisphosphonate associated
ONJ includes the following features:
1. Current or previous treatment with a bisphosphonate
2. Exposed bone in the maxillofacial region that per-
sisted for greater than 8 weeks and
3. No history of radiation therapy to the jaws [47].
An attempt also has been made to define clinical
stages of ONJ [45,48] (AAOMS, 2007). Stage 1 involved
the presence of exposed or necrotic bone that is asymp-
tomatic with no evidence of infection. Stage 2 related to
t h ep r e s e n c eo fe x p o s e dn e c r o t i cb o n ea n di n f e c t i o n ,
erythema and the presence or absence of a purulent dis-
charge. Finally stage 3, the most severe form of ONJ,
contained all the characteristics of stage 2 but in addi-
tion, the presence of features such as a pathological
fracture, draining sinus or communication either intra
oral or extraoral and osteolysis. Since then, Stage 0 has
been included to encompass patients with signs of ONJ
but no exposed bone [46].
Potential covariates to be collected in this study are in
line with those suggested as risk factors for ONJ and
include dental factors such as tooth extraction, implant
placement and denture use, treatment factors such as
use of glucocortocoids and smoking status [26,29,49].
A critical component to the success or failure of any
case-controlled study is recruitment of participants. The
study was designed as a two-step recruitment process
requiring not only patient participation but also clinician
participation otherwise access to patient data and poten-
tial cases would have not been possible without employ-
ing more complex recruitment protocols. It is also
imperative we seek the assistance of specialist practi-
tioners in order to gain permission to screen consecutive
patient records during the defined study time period in
order to avoid selection bias associated with specialist
recall of individual patient cases. Hence there are two
potential problems with recruitment. The first lies with
recruiting specialists. A number of key features have been
identified to be essential to increase response rates in
postal questionnaires [50]. A number of these features
are also pertinent in the following study. Firstly, Edwards
et al., (2002) suggested that contacting participants before
sending out questionnaires would be important. In the
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Page 8 of 10current study, the researchers presented the study outline
and requirements of participants (clinician and patient)
to oral and maxillofacial surgeons at a continuing profes-
sional development meeting. It is considered crucial to
the study to recruit a high proportion of oral and maxil-
lofacial surgeons as these are recognized as the group
most likely to treat patients delayed dental healing follow-
ing dental procedures. During this presentation the
potential benefits of determining incidence of delayed
dental healing with reference to bisphosphonate usage
were discussed, which was considered to be of great
interest to practicing specialists. This has also been deter-
mined as a potential method to increase response rate to
postal surveys [50].
Other key factors employed to increase clinician
recruitment included using personalized introductory
letters, short questionnaires, follow-up letters to non-
respondents and telephone follow-up. These are recog-
nized strategies to increase recruitment [50]. Similar
measures were also employed when recruiting potential
cases and controls.
Conclusions
The study uses a case-controlled design to assess the
hypothesis that long-term (more than 1 year’s duration)
bisphosphonate use for the treatment of postmenopausal
osteoporosis or other benign bone disease is associated
with impaired dental healing and subsequent develop-
ment of ONJ. All Victorian Oral and Maxillofacial Sur-
geons and Special Needs Dentists, by far the largest
groups managing these patients, will be invited to parti-
cipate making this the largest such study in Australia.
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